3-hydroxy-2-(1H-indol-3-ylmethyl)-5-oxo-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester | 1174654-76-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-hydroxy-2-(1H-indol-3-ylmethyl)-5-oxo-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl (2R)-3-hydroxy-2-(1H-indol-3-ylmethyl)-5-oxo-2H-pyrrole-1-carboxylate
• CAS: 1174654-76-2
• 化学式: C₁₈H₂₀N₂O₄
• 分子量: 328.368
• InChiKey: YFKCJLYURWKFPN-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  82.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-hydroxy-2-(1H-indol-3-ylmethyl)-5-oxo-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 (S)-5-((1H-indol-3-yl)methyl)pyrrolidine-2,4-dione
  参考文献：
  名称：

  Expanding the Scope of Oligo-pyrrolinone–Pyrrolidines as Protein–Protein Interface Mimics

  摘要：

  Oligo-pyrrolinone-pyrrolidines (generic structure 1) have the potential to interfere with protein-protein interactions (PPIs), but to reduce this to practice it is necessary to be able to synthesize these structures with a variety of different side chains corresponding to genetically encoded proteins. This paper describes expansion of the synthetic scope of 1, the difficulties encountered in this process, particularly issues with epimerization and slow coupling rates, and methods to overcome them. Finally, spectroscopic and physicochemical properties as well as proteolytic stabilities of molecules in this series were measured; these data highlight the suitability of oligo-pyrrolinone-pyrrolidines for the development of pharmacological probes or pharmaceutical leads.

  DOI：

  10.1021/jo400323k
• 作为产物：
  描述：

  BOC-D-色氨酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 14.5h， 生成 3-hydroxy-2-(1H-indol-3-ylmethyl)-5-oxo-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Expanding the Scope of Oligo-pyrrolinone–Pyrrolidines as Protein–Protein Interface Mimics

  摘要：

  Oligo-pyrrolinone-pyrrolidines (generic structure 1) have the potential to interfere with protein-protein interactions (PPIs), but to reduce this to practice it is necessary to be able to synthesize these structures with a variety of different side chains corresponding to genetically encoded proteins. This paper describes expansion of the synthetic scope of 1, the difficulties encountered in this process, particularly issues with epimerization and slow coupling rates, and methods to overcome them. Finally, spectroscopic and physicochemical properties as well as proteolytic stabilities of molecules in this series were measured; these data highlight the suitability of oligo-pyrrolinone-pyrrolidines for the development of pharmacological probes or pharmaceutical leads.

  DOI：

  10.1021/jo400323k

文献信息

• [EN] IAP INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINES D'APOPTOSE
  申请人：TETRALOGIC PHARMACEUTICAL CORP

  公开号：WO2009094287A1

  公开（公告）日：2009-07-30

  The present invention describes compounds of the following formula: processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. The compounds of the present invention inhibit IAPs (inhibitors of apoptosis proteins) and thus are useful in the treatment of cancer, autoimmune diseases and other disorders where a defect in apoptosis is implicated.

  本发明描述了以下式的化合物：它们的制备方法，含有它们的药物组合物，以及它们在治疗中的应用。本发明的化合物抑制IAPs（凋亡抑制蛋白），因此在癌症、自身免疫疾病和其他凋亡缺陷相关疾病的治疗中具有用处。
• IAP INHIBITORS
  申请人：Condon Stephen M.

  公开号：US20110288116A1

  公开（公告）日：2011-11-24

  The present invention describes compounds of the following formula: processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. The compounds of the present invention inhibit IAPs (inhibitors of apoptosis proteins) and thus are useful in the treatment of cancer, autoimmune diseases and other disorders where a defect in apoptosis is implicated.

  本发明描述了以下式子的化合物：它们的制备过程、含有它们的药物组合物以及它们在治疗中的应用。本发明的化合物抑制IAPs（凋亡抑制蛋白），因此在治疗癌症、自身免疫性疾病和其他涉及凋亡缺陷的疾病中很有用。
• Cytotoxic Tetramic Acid Derivative Produced by a Plant Type-III Polyketide Synthase
  作者：Toshiyuki Wakimoto、Takahiro Mori、Hiroyuki Morita、Ikuro Abe

  DOI：10.1021/ja2006737

  日期：2011.4.6

  The tetramic acid (2,4-pyrrolidinedione) scaffold has been recognized as an important structural feature because of its mycotoxic, antibacterial, antiviral, and antioxidant activities. This important class of natural products is reportedly produced by the type-I polyketide synthase/nonribosomal peptide synthetase (PKS/NRPS) hybrid megaenzyme systems. In contrast, the benzalacetone synthase (BAS) from Rheum palmatum is a structurally simple, plant-specific type-III PKS that catalyzes the one-step decarboxylative condensation of malonyl-CoA with 4-coumaroyl-CoA. The type-III PKS exhibits unusually broad substrate specificity and notable catalytic versatility. Here we report that R. palmatum BAS efficiently produces a series of unnatural, novel tetramic acid derivatives by the condensation of malonyl-CoA with aminoacyl-CoA thioesters chemically synthesized from L- and D-amino acids. Remarkably, the novel tetramic acid dimer ID-S formed from D-phenylalanoyl-CoA showed moderate antiproliferative activity against murine leukemia P388 cells.
• Expanding the Scope of Oligo-pyrrolinone–Pyrrolidines as Protein–Protein Interface Mimics
  作者：Arjun Raghuraman、Dongyue Xin、Lisa M. Perez、Kevin Burgess

  DOI：10.1021/jo400323k

  日期：2013.5.17

  Oligo-pyrrolinone-pyrrolidines (generic structure 1) have the potential to interfere with protein-protein interactions (PPIs), but to reduce this to practice it is necessary to be able to synthesize these structures with a variety of different side chains corresponding to genetically encoded proteins. This paper describes expansion of the synthetic scope of 1, the difficulties encountered in this process, particularly issues with epimerization and slow coupling rates, and methods to overcome them. Finally, spectroscopic and physicochemical properties as well as proteolytic stabilities of molecules in this series were measured; these data highlight the suitability of oligo-pyrrolinone-pyrrolidines for the development of pharmacological probes or pharmaceutical leads.